MONTREAL--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) will present new data on the company’s leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada. Nearly 20 presentations will focus on the company’s products: TYSABRI® (natalizumab), which offers MS patients a new level of efficacy, and AVONEX® (Interferon beta-1a), the most prescribed MS therapy worldwide, as well as its pipeline featuring compounds targeting unique approaches for development in MS. These data will provide physicians with important new information on the benefits of TYSABRI and AVONEX, and update the MS community on the company’s progress with three of its investigational compounds for MS: daclizumab, RITUXAN® (rituximab) and BG-12 (dimethyl fumarate), the company’s novel, oral compound in Phase III trials.
